---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071674"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:03:49.292359+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Q4 2025 GAAP revenue $284M; FY25 $1.07B; NUPLAZID $174M, DAYBUE $110M; FY26 guidance $1.22-1.28B

## Summary
- Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.
- GAAP NUPLAZID net sales $174M (includes $20M IRA rebate adjustment); non-GAAP adjusted $189M, up 17% vs Q4 2024.
- DAYBUE net sales $110M in Q4 (+13% YoY) and $391M for FY25.
- Net income Q4 $274M ($1.60 diluted EPS) including $250M tax benefit; FY net income $391M ($2.30 EPS). Cash & investments $820M.
- FY 2026 guidance: total revenue $1.22-1.28B; NUPLAZID $760-790M; DAYBUE $460-490M; R&D $385-410M; SG&A $660-700M.

## SEC filing metadata
- accession: 0001193125-26-071674
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/0001193125-26-071674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526071674/acad-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071674
- JSON: https://secwatch.observer/filing/0001193125-26-071674.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071674.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.